Effectiveness of CAR-T treatment toward the potential risk of second malignancies.
作者信息
Martino Massimo, Porto Gaetana, Policastro Giorgia, Alati Caterina, Loteta Barbara, Micó Maria Caterina, Argiró Clizia, Altomonte Maria, Moscato Tiziana, Labate Demetrio, Dattola Vincenzo, Rao Carmelo Massimiliano, Cogliandro Francesca, Canale Filippo Antonio, Naso Virginia, Filippelli Gianfranco, Iaria Antonino, Pitea Martina
机构信息
Stem Cell Transplantation and Cellular Therapies Unit (CTMO), Department of Hemato-Oncology and Radiotherapy, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
CAR-T Multidisciplinary Team, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli,", Reggio Calabria, Italy.
出版信息
Front Immunol. 2024 May 2;15:1384002. doi: 10.3389/fimmu.2024.1384002. eCollection 2024.
Abstract
摘要
相似文献
1
Effectiveness of CAR-T treatment toward the potential risk of second malignancies.嵌合抗原受体T细胞（CAR-T）疗法对继发性恶性肿瘤潜在风险的有效性。
Front Immunol. 2024 May 2;15:1384002. doi: 10.3389/fimmu.2024.1384002. eCollection 2024.
2
The Fate(s) of CAR T-Cell Therapy: Navigating the Risks of CAR+ T-Cell Malignancy.嵌合抗原受体 T 细胞疗法的命运：应对嵌合抗原受体 T 细胞肿瘤的风险。
Blood Cancer Discov. 2024 Jul 1;5(4):249-257. doi: 10.1158/2643-3230.BCD-23-0272.
3
Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.CAR-T细胞疗法后继发性血液系统肿瘤的罕见性与风险
Transplant Cell Ther. 2024 Oct;30(10):936-938. doi: 10.1016/j.jtct.2024.09.002.
4
Chimeric Antigen Receptor (CAR) T-Cell Therapy.嵌合抗原受体（CAR）T细胞疗法
JAMA Oncol. 2017 Nov 1;3(11):1595. doi: 10.1001/jamaoncol.2017.2989.
5
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.嵌合抗原受体 T 细胞（CAR T）治疗后第二原发恶性肿瘤：5517 例淋巴瘤和骨髓瘤患者的系统评价和荟萃分析。
Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798.
6
CAR T-Cells and Safety Signals: ITT Episode 29.嵌合抗原受体T细胞与安全信号：ITT第29集。
N Engl J Med. 2024 Apr 25;390(16):e39. doi: 10.1056/NEJMp2400701.
7
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System.商业 CAR T 细胞治疗后的第二原发性恶性肿瘤：FDA 不良事件报告系统分析。
Blood. 2024 May 16;143(20):2099-2105. doi: 10.1182/blood.2024024166.
8
CAR T Cell Therapy for Hematological Malignancies.嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤。
Curr Med Sci. 2019 Dec;39(6):874-882. doi: 10.1007/s11596-019-2118-z. Epub 2019 Dec 16.
9
Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.嵌合抗原受体 T 细胞（CAR-T）疗法在癌症中的风险和益处：系统评价和荟萃分析。
Transfus Med Rev. 2019 Apr;33(2):98-110. doi: 10.1016/j.tmrv.2019.01.005. Epub 2019 Feb 14.
10
Data mining for second malignancies after CAR-T.嵌合抗原受体T细胞疗法（CAR-T）后第二原发性恶性肿瘤的数据挖掘
Blood. 2024 May 16;143(20):2023-2024. doi: 10.1182/blood.2024024446.
本文引用的文献
1
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.商业 CAR T 细胞治疗后 T 细胞淋巴瘤和继发原发性恶性肿瘤风险。
Nat Med. 2024 Apr;30(4):984-989. doi: 10.1038/s41591-024-02826-w. Epub 2024 Jan 24.
2
CAR-T Cell Therapy for Follicular Lymphomas.嵌合抗原受体T细胞疗法治疗滤泡性淋巴瘤
Mediterr J Hematol Infect Dis. 2024 Jan 1;16(1):e2024012. doi: 10.4084/MJHID.2024.012. eCollection 2024.
3
Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.嵌合抗原受体 T 细胞疗法在 B 细胞淋巴瘤患者中面临的挑战。
Ann Lab Med. 2024 May 1;44(3):210-221. doi: 10.3343/alm.2023.0388. Epub 2024 Jan 11.
4
Chimeric Antigen Receptor-T Cell Therapy for Lymphoma: New Settings and Future Directions.嵌合抗原受体T细胞疗法治疗淋巴瘤：新的应用场景与未来方向
Cancers (Basel). 2023 Dec 21;16(1):46. doi: 10.3390/cancers16010046.
5
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法后出现继发性恶性肿瘤报告后的未解问题。
Nat Med. 2024 Feb;30(2):338-341. doi: 10.1038/s41591-023-02767-w.
6
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.tisagenlecleucel治疗复发/难治性滤泡性淋巴瘤成人患者后的持久缓解：ELARA试验更新
Blood. 2024 Apr 25;143(17):1713-1725. doi: 10.1182/blood.2023021567.
7
Recent advances and current challenges in CAR-T cell therapy.嵌合抗原受体T细胞（CAR-T）疗法的最新进展与当前挑战
Biotechnol Lett. 2024 Feb;46(1):115-126. doi: 10.1007/s10529-023-03461-0. Epub 2023 Dec 27.
8
Integrating CAR-T cell therapy into the management of DLBCL: what we are learning.将嵌合抗原受体 T 细胞疗法融入弥漫性大 B 细胞淋巴瘤的治疗：我们的学习心得。
Expert Opin Biol Ther. 2023 Jul-Dec;23(12):1277-1285. doi: 10.1080/14712598.2023.2292634. Epub 2023 Dec 28.
9
Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001.TRANSCEND NHL 001 研究中接受乐西妥珠单抗治疗的复发/难治性大 B 细胞淋巴瘤患者的 2 年随访结果
Blood. 2024 Feb 1;143(5):404-416. doi: 10.1182/blood.2023020854.
10
Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma.西达基奥仑赛，一种用于经大量预处理的复发/难治性多发性骨髓瘤患者的靶向B细胞成熟抗原（BCMA）的嵌合抗原受体T细胞（CAR-T）疗法。
Future Oncol. 2023 Nov;19(34):2297-2311. doi: 10.2217/fon-2022-1317. Epub 2023 Jul 27.
Zotero 插件